Initial inhaler choice in COPD: real-world evidence

In a real-world cohort (UK's CPRD), initiating inhaled treatment for COPD with ICS/LABA rather than LAMA improves exacerbation rate without significant increases in pneumonia rates in those with peripheral blood eosinophil counts >4% http://bit.ly/2OZpij5

Detalles Bibliográficos
Autor principal: Jones, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Expert Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885333/
https://www.ncbi.nlm.nih.gov/pubmed/31803273
http://dx.doi.org/10.1183/20734735.0256-2019
Descripción
Sumario:In a real-world cohort (UK's CPRD), initiating inhaled treatment for COPD with ICS/LABA rather than LAMA improves exacerbation rate without significant increases in pneumonia rates in those with peripheral blood eosinophil counts >4% http://bit.ly/2OZpij5

Ejemplares similares